Recombinant antibodies for immunotherapy:
Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunoge...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Cambridge University Press
2009
|
| Schlagworte: | |
| Online-Zugang: | BSB01 FHN01 Volltext |
| Zusammenfassung: | Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors |
| Beschreibung: | Title from publisher's bibliographic system (viewed on 05 Oct 2015) |
| Beschreibung: | 1 online resource (xiv, 419 pages) |
| ISBN: | 9780511596773 |
| DOI: | 10.1017/CBO9780511596773 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043945025 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161206s2009 |||| o||u| ||||||eng d | ||
| 020 | |a 9780511596773 |c Online |9 978-0-511-59677-3 | ||
| 024 | 7 | |a 10.1017/CBO9780511596773 |2 doi | |
| 035 | |a (ZDB-20-CBO)CR9780511596773 | ||
| 035 | |a (OCoLC)838251933 | ||
| 035 | |a (DE-599)BVBBV043945025 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-92 | ||
| 082 | 0 | |a 615/.37 |2 22 | |
| 084 | |a VS 9400 |0 (DE-625)147728:253 |2 rvk | ||
| 245 | 1 | 0 | |a Recombinant antibodies for immunotherapy |c edited by Melvyn Little |
| 264 | 1 | |a Cambridge |b Cambridge University Press |c 2009 | |
| 300 | |a 1 online resource (xiv, 419 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from publisher's bibliographic system (viewed on 05 Oct 2015) | ||
| 505 | 8 | |a Humanization of recombinant antibodies / José W. Saldanha -- Immunogenicity assessment of antibody therapeutics / Philippe Stas [and others] -- In vitro screening for antibody immunogenicity / Frank J. Carr and Matthew B. Baker -- Antibody libraries from naïve V gene sources / Gerald Beste and David Lowe -- Antibodies from IgM libraries / Stefan Knackmuss and Vera Molkenthin -- Generation and screening of synthetic human combinatorial antibody library HuCAL GOLD / Ingo M. Klagge -- Therapeutic antibodies from XenoMouse transgenic mice / Aya Jakobovits -- VelocImmune : immunoglobulin variable region humanized mice / Andrew Murphy -- Mechanisms of tumour cell killing by therapeutic antibodies / Ross Stewart and Carl Webster -- Optimization of Fc domains to enhance antibody therapeutics / Greg A. Lazar and Aaron K. Chamberlain -- Glycoengineered therapeutic antibodies / Peter Brünker, Peter Sondermann, and Pablo Umaña -- Monoclonal antibodies for the delivery of cytotoxic drugs / David J. King | |
| 505 | 8 | |a Immunotherapy with radio-immune conjugates / Christina A. Kousparou and Agamemnon A. Epenetos -- Immunotherapeutic antibody fusion proteins / Nigel S. Courtenay-Luck and David Jones -- Alternative antibody formats / Fabrice Le Gall and Melvyn Little -- Single-domain antibodies / Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens -- Engineering of non-CDR loops in immunoglobulin domains / Florian Rüker and Gordana Wozniak-Knopp -- Alternative scaffolds : expanding the options of antibodies / Andreas Plückthun -- Polymer fusions to increase antibody half-lives : PEGylation and other modifications / Sam P. Heywood and David P. Humphreys -- Extending antibody half-lives with albumin / Jan Terje Andersen and Inger Sandlie -- A stem cell-based platform for the discovery and development of antitumor therapeutic antibodies to novel targets / Jennie P. Mather [and others] -- Antibody directed enzyme prodrug therapy (ADEPT) / Helen L. Lowe [and others] -- Immune privilege and tolerance -- therapeutic antibody approaches / Daron Forman [and others] -- Antibody therapeutics : business achievements and business outlook / Christophe Bourrilly | |
| 520 | |a Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors | ||
| 650 | 4 | |a Monoclonal antibodies / Therapeutic use | |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Technologie |0 (DE-588)4045699-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Rekombinantes Protein |0 (DE-588)4277353-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |D s |
| 689 | 0 | 1 | |a Rekombinantes Protein |0 (DE-588)4277353-2 |D s |
| 689 | 0 | 2 | |a Pharmazeutische Technologie |0 (DE-588)4045699-7 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 689 | 1 | 0 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |D s |
| 689 | 1 | 1 | |a Rekombinantes Protein |0 (DE-588)4277353-2 |D s |
| 689 | 1 | 2 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 1 | |8 3\p |5 DE-604 | |
| 700 | 1 | |a Little, Melvyn |d 1945- |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-88732-8 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/CBO9780511596773 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-20-CBO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029353995 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511596773 |l BSB01 |p ZDB-20-CBO |q BSB_PDA_CBO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511596773 |l FHN01 |p ZDB-20-CBO |q FHN_PDA_CBO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176890700759040 |
|---|---|
| any_adam_object | |
| author2 | Little, Melvyn 1945- |
| author2_role | edt |
| author2_variant | m l ml |
| author_facet | Little, Melvyn 1945- |
| building | Verbundindex |
| bvnumber | BV043945025 |
| classification_rvk | VS 9400 |
| collection | ZDB-20-CBO |
| contents | Humanization of recombinant antibodies / José W. Saldanha -- Immunogenicity assessment of antibody therapeutics / Philippe Stas [and others] -- In vitro screening for antibody immunogenicity / Frank J. Carr and Matthew B. Baker -- Antibody libraries from naïve V gene sources / Gerald Beste and David Lowe -- Antibodies from IgM libraries / Stefan Knackmuss and Vera Molkenthin -- Generation and screening of synthetic human combinatorial antibody library HuCAL GOLD / Ingo M. Klagge -- Therapeutic antibodies from XenoMouse transgenic mice / Aya Jakobovits -- VelocImmune : immunoglobulin variable region humanized mice / Andrew Murphy -- Mechanisms of tumour cell killing by therapeutic antibodies / Ross Stewart and Carl Webster -- Optimization of Fc domains to enhance antibody therapeutics / Greg A. Lazar and Aaron K. Chamberlain -- Glycoengineered therapeutic antibodies / Peter Brünker, Peter Sondermann, and Pablo Umaña -- Monoclonal antibodies for the delivery of cytotoxic drugs / David J. King Immunotherapy with radio-immune conjugates / Christina A. Kousparou and Agamemnon A. Epenetos -- Immunotherapeutic antibody fusion proteins / Nigel S. Courtenay-Luck and David Jones -- Alternative antibody formats / Fabrice Le Gall and Melvyn Little -- Single-domain antibodies / Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens -- Engineering of non-CDR loops in immunoglobulin domains / Florian Rüker and Gordana Wozniak-Knopp -- Alternative scaffolds : expanding the options of antibodies / Andreas Plückthun -- Polymer fusions to increase antibody half-lives : PEGylation and other modifications / Sam P. Heywood and David P. Humphreys -- Extending antibody half-lives with albumin / Jan Terje Andersen and Inger Sandlie -- A stem cell-based platform for the discovery and development of antitumor therapeutic antibodies to novel targets / Jennie P. Mather [and others] -- Antibody directed enzyme prodrug therapy (ADEPT) / Helen L. Lowe [and others] -- Immune privilege and tolerance -- therapeutic antibody approaches / Daron Forman [and others] -- Antibody therapeutics : business achievements and business outlook / Christophe Bourrilly |
| ctrlnum | (ZDB-20-CBO)CR9780511596773 (OCoLC)838251933 (DE-599)BVBBV043945025 |
| dewey-full | 615/.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.37 |
| dewey-search | 615/.37 |
| dewey-sort | 3615 237 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| doi_str_mv | 10.1017/CBO9780511596773 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05712nmm a2200613zc 4500</leader><controlfield tag="001">BV043945025</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161206s2009 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780511596773</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-511-59677-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1017/CBO9780511596773</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-20-CBO)CR9780511596773</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)838251933</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043945025</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-92</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.37</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9400</subfield><subfield code="0">(DE-625)147728:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recombinant antibodies for immunotherapy</subfield><subfield code="c">edited by Melvyn Little</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xiv, 419 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from publisher's bibliographic system (viewed on 05 Oct 2015)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Humanization of recombinant antibodies / José W. Saldanha -- Immunogenicity assessment of antibody therapeutics / Philippe Stas [and others] -- In vitro screening for antibody immunogenicity / Frank J. Carr and Matthew B. Baker -- Antibody libraries from naïve V gene sources / Gerald Beste and David Lowe -- Antibodies from IgM libraries / Stefan Knackmuss and Vera Molkenthin -- Generation and screening of synthetic human combinatorial antibody library HuCAL GOLD / Ingo M. Klagge -- Therapeutic antibodies from XenoMouse transgenic mice / Aya Jakobovits -- VelocImmune : immunoglobulin variable region humanized mice / Andrew Murphy -- Mechanisms of tumour cell killing by therapeutic antibodies / Ross Stewart and Carl Webster -- Optimization of Fc domains to enhance antibody therapeutics / Greg A. Lazar and Aaron K. Chamberlain -- Glycoengineered therapeutic antibodies / Peter Brünker, Peter Sondermann, and Pablo Umaña -- Monoclonal antibodies for the delivery of cytotoxic drugs / David J. King</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Immunotherapy with radio-immune conjugates / Christina A. Kousparou and Agamemnon A. Epenetos -- Immunotherapeutic antibody fusion proteins / Nigel S. Courtenay-Luck and David Jones -- Alternative antibody formats / Fabrice Le Gall and Melvyn Little -- Single-domain antibodies / Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens -- Engineering of non-CDR loops in immunoglobulin domains / Florian Rüker and Gordana Wozniak-Knopp -- Alternative scaffolds : expanding the options of antibodies / Andreas Plückthun -- Polymer fusions to increase antibody half-lives : PEGylation and other modifications / Sam P. Heywood and David P. Humphreys -- Extending antibody half-lives with albumin / Jan Terje Andersen and Inger Sandlie -- A stem cell-based platform for the discovery and development of antitumor therapeutic antibodies to novel targets / Jennie P. Mather [and others] -- Antibody directed enzyme prodrug therapy (ADEPT) / Helen L. Lowe [and others] -- Immune privilege and tolerance -- therapeutic antibody approaches / Daron Forman [and others] -- Antibody therapeutics : business achievements and business outlook / Christophe Bourrilly</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monoclonal antibodies / Therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Technologie</subfield><subfield code="0">(DE-588)4045699-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rekombinantes Protein</subfield><subfield code="0">(DE-588)4277353-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Rekombinantes Protein</subfield><subfield code="0">(DE-588)4277353-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pharmazeutische Technologie</subfield><subfield code="0">(DE-588)4045699-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Rekombinantes Protein</subfield><subfield code="0">(DE-588)4277353-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Little, Melvyn</subfield><subfield code="d">1945-</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-88732-8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1017/CBO9780511596773</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-20-CBO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029353995</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511596773</subfield><subfield code="l">BSB01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">BSB_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511596773</subfield><subfield code="l">FHN01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">FHN_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV043945025 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:39:22Z |
| institution | BVB |
| isbn | 9780511596773 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029353995 |
| oclc_num | 838251933 |
| open_access_boolean | |
| owner | DE-12 DE-92 |
| owner_facet | DE-12 DE-92 |
| physical | 1 online resource (xiv, 419 pages) |
| psigel | ZDB-20-CBO ZDB-20-CBO BSB_PDA_CBO ZDB-20-CBO FHN_PDA_CBO |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | Cambridge University Press |
| record_format | marc |
| spelling | Recombinant antibodies for immunotherapy edited by Melvyn Little Cambridge Cambridge University Press 2009 1 online resource (xiv, 419 pages) txt rdacontent c rdamedia cr rdacarrier Title from publisher's bibliographic system (viewed on 05 Oct 2015) Humanization of recombinant antibodies / José W. Saldanha -- Immunogenicity assessment of antibody therapeutics / Philippe Stas [and others] -- In vitro screening for antibody immunogenicity / Frank J. Carr and Matthew B. Baker -- Antibody libraries from naïve V gene sources / Gerald Beste and David Lowe -- Antibodies from IgM libraries / Stefan Knackmuss and Vera Molkenthin -- Generation and screening of synthetic human combinatorial antibody library HuCAL GOLD / Ingo M. Klagge -- Therapeutic antibodies from XenoMouse transgenic mice / Aya Jakobovits -- VelocImmune : immunoglobulin variable region humanized mice / Andrew Murphy -- Mechanisms of tumour cell killing by therapeutic antibodies / Ross Stewart and Carl Webster -- Optimization of Fc domains to enhance antibody therapeutics / Greg A. Lazar and Aaron K. Chamberlain -- Glycoengineered therapeutic antibodies / Peter Brünker, Peter Sondermann, and Pablo Umaña -- Monoclonal antibodies for the delivery of cytotoxic drugs / David J. King Immunotherapy with radio-immune conjugates / Christina A. Kousparou and Agamemnon A. Epenetos -- Immunotherapeutic antibody fusion proteins / Nigel S. Courtenay-Luck and David Jones -- Alternative antibody formats / Fabrice Le Gall and Melvyn Little -- Single-domain antibodies / Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens -- Engineering of non-CDR loops in immunoglobulin domains / Florian Rüker and Gordana Wozniak-Knopp -- Alternative scaffolds : expanding the options of antibodies / Andreas Plückthun -- Polymer fusions to increase antibody half-lives : PEGylation and other modifications / Sam P. Heywood and David P. Humphreys -- Extending antibody half-lives with albumin / Jan Terje Andersen and Inger Sandlie -- A stem cell-based platform for the discovery and development of antitumor therapeutic antibodies to novel targets / Jennie P. Mather [and others] -- Antibody directed enzyme prodrug therapy (ADEPT) / Helen L. Lowe [and others] -- Immune privilege and tolerance -- therapeutic antibody approaches / Daron Forman [and others] -- Antibody therapeutics : business achievements and business outlook / Christophe Bourrilly Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors Monoclonal antibodies / Therapeutic use Immuntherapie (DE-588)4026640-0 gnd rswk-swf Pharmazeutische Technologie (DE-588)4045699-7 gnd rswk-swf Monoklonaler Antikörper (DE-588)4040094-3 gnd rswk-swf Rekombinantes Protein (DE-588)4277353-2 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Monoklonaler Antikörper (DE-588)4040094-3 s Rekombinantes Protein (DE-588)4277353-2 s Pharmazeutische Technologie (DE-588)4045699-7 s 2\p DE-604 Immuntherapie (DE-588)4026640-0 s 3\p DE-604 Little, Melvyn 1945- edt Erscheint auch als Druckausgabe 978-0-521-88732-8 https://doi.org/10.1017/CBO9780511596773 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Recombinant antibodies for immunotherapy Humanization of recombinant antibodies / José W. Saldanha -- Immunogenicity assessment of antibody therapeutics / Philippe Stas [and others] -- In vitro screening for antibody immunogenicity / Frank J. Carr and Matthew B. Baker -- Antibody libraries from naïve V gene sources / Gerald Beste and David Lowe -- Antibodies from IgM libraries / Stefan Knackmuss and Vera Molkenthin -- Generation and screening of synthetic human combinatorial antibody library HuCAL GOLD / Ingo M. Klagge -- Therapeutic antibodies from XenoMouse transgenic mice / Aya Jakobovits -- VelocImmune : immunoglobulin variable region humanized mice / Andrew Murphy -- Mechanisms of tumour cell killing by therapeutic antibodies / Ross Stewart and Carl Webster -- Optimization of Fc domains to enhance antibody therapeutics / Greg A. Lazar and Aaron K. Chamberlain -- Glycoengineered therapeutic antibodies / Peter Brünker, Peter Sondermann, and Pablo Umaña -- Monoclonal antibodies for the delivery of cytotoxic drugs / David J. King Immunotherapy with radio-immune conjugates / Christina A. Kousparou and Agamemnon A. Epenetos -- Immunotherapeutic antibody fusion proteins / Nigel S. Courtenay-Luck and David Jones -- Alternative antibody formats / Fabrice Le Gall and Melvyn Little -- Single-domain antibodies / Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens -- Engineering of non-CDR loops in immunoglobulin domains / Florian Rüker and Gordana Wozniak-Knopp -- Alternative scaffolds : expanding the options of antibodies / Andreas Plückthun -- Polymer fusions to increase antibody half-lives : PEGylation and other modifications / Sam P. Heywood and David P. Humphreys -- Extending antibody half-lives with albumin / Jan Terje Andersen and Inger Sandlie -- A stem cell-based platform for the discovery and development of antitumor therapeutic antibodies to novel targets / Jennie P. Mather [and others] -- Antibody directed enzyme prodrug therapy (ADEPT) / Helen L. Lowe [and others] -- Immune privilege and tolerance -- therapeutic antibody approaches / Daron Forman [and others] -- Antibody therapeutics : business achievements and business outlook / Christophe Bourrilly Monoclonal antibodies / Therapeutic use Immuntherapie (DE-588)4026640-0 gnd Pharmazeutische Technologie (DE-588)4045699-7 gnd Monoklonaler Antikörper (DE-588)4040094-3 gnd Rekombinantes Protein (DE-588)4277353-2 gnd |
| subject_GND | (DE-588)4026640-0 (DE-588)4045699-7 (DE-588)4040094-3 (DE-588)4277353-2 (DE-588)4143413-4 |
| title | Recombinant antibodies for immunotherapy |
| title_auth | Recombinant antibodies for immunotherapy |
| title_exact_search | Recombinant antibodies for immunotherapy |
| title_full | Recombinant antibodies for immunotherapy edited by Melvyn Little |
| title_fullStr | Recombinant antibodies for immunotherapy edited by Melvyn Little |
| title_full_unstemmed | Recombinant antibodies for immunotherapy edited by Melvyn Little |
| title_short | Recombinant antibodies for immunotherapy |
| title_sort | recombinant antibodies for immunotherapy |
| topic | Monoclonal antibodies / Therapeutic use Immuntherapie (DE-588)4026640-0 gnd Pharmazeutische Technologie (DE-588)4045699-7 gnd Monoklonaler Antikörper (DE-588)4040094-3 gnd Rekombinantes Protein (DE-588)4277353-2 gnd |
| topic_facet | Monoclonal antibodies / Therapeutic use Immuntherapie Pharmazeutische Technologie Monoklonaler Antikörper Rekombinantes Protein Aufsatzsammlung |
| url | https://doi.org/10.1017/CBO9780511596773 |
| work_keys_str_mv | AT littlemelvyn recombinantantibodiesforimmunotherapy |